A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017

Type 2 Diabetes Mellitus Clinical Trial

Official title:

Prevalence of Cardiovascular Disease in Swedish Patients With Type 2 Diabetes and in Patients Initiating on Empagliflozin

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04927858
• Other study ID #: 1245-0190
• Status: Completed
• Start date: April 2, 2018
• Est. completion date: November 15, 2018

Study information

• Verified date: July 2021
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims to describe the prevalence of type 2 diabetes mellitus (T2DM) patients with established cardiovascular disease (CVD) according to the (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME (ERO)) study definition in a Swedish population. The aim was also to describe the prevalence of established CVD according to ERO study definition in patients with T2DM who initiates treatment with empagliflozin

Recruitment information / eligibility

• Status: Completed
• Enrollment: 460558
• Est. completion date: November 15, 2018
• Est. primary completion date: November 15, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria Population 1: 'Prevalence of a history of cardiovascular disease (CVD) among persons with

type 2 diabetes mellitus (T2DM) who were alive on 31 December 2017' :

• Diagnosed with T2DM in Sweden
• Alive on 31 December 2017
• At least one registration in the Swedish National Diabetes Register (NDR)
• Each patient provides informed consent for inclusion in the register Population 2: 'Prevalence of a history of CVD among persons with type 2 diabetes who

started empagliflozin treatment between 1 January 2015 and 31 December 2017':

• Diagnosed with T2DM in Sweden
• Alive on 31 December 2017
• Initiated on empagliflozin between 1 January 2015 and 31 December 2017
• At least one registration in the NDR
• Each patient provides informed consent for inclusion in the register Exclusion criteria: none

Related Conditions & MeSH terms

• Cardiovascular Diseases
• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes Mellitus

Intervention

Drug:
• Empagliflozin
Empagliflozin

Locations

Country	Name	City	State
Sweden	Boehringer Ingelheim AB	Stockholm

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of a History of Cardiovascular Disease (CVD) Among Swedish Patients With Type 2 Diabetes Mellitus (T2DM) Who Were Alive on 31st of December 2017	The number of participants with a history of CVD and without a history of CVD among patients who had Type 2 Diabetes Mellitus (T2DM) and were = 18 years old on 31st of December 2017, and were alive on 31st of December 2017, and had at least one registration in the Swedish National Diabetes Registry (NDR) between 1996 - 2017 is reported. History of CVD was defined as a history of either coronary heart disease, stroke, amputation, percutaneous coronary intervention, coronary artery bypass surgery, peripheral vascular disease, or carotid or femoral angioplasty.	Data collected at the index date 31st of December 2017, data covering a time period from 1996 until 2017, up to 21 years.
Primary	Prevalence of a History of CVD Among Swedish Patients With T2DM Who Started Empagliflozin Treatment Between 1st of January 2015 and 31st of December 2017	The number of participants with a history of CVD and without a history of CVD among patients with Type 2 Diabetes Mellitus (T2DM) who were initiated on Empagliflozin between 1st of January 2015 and 31st of December 2017, who had at least one registration in the Swedish National Diabetes Register (NDR). History of CVD was defined as a history of either coronary heart disease, stroke, amputation, percutaneous coronary intervention, coronary artery bypass surgery, peripheral vascular disease, or carotid or femoral angioplasty.	Data collected at the index date 31st of December 2017, data covering a time period from 1996 until 2017, up to 21 years.

External Links

•   Related info